Skip to content

Comparing the Efficacy of Oral Opioids for Outpatient Acute Pain Management After ED Discharge Discharge

Comparing the Efficacy of Oral Opioids for Outpatient Acute Pain Management After ED Discharge

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01402375
Enrollment
720
Registered
2011-07-26
Start date
2012-01-31
Completion date
2014-11-30
Last updated
2018-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Analgesia After ED Discharge for Extremity Injuries

Keywords

Pain Management, Emergency Medicine, Extremity Injuries

Brief summary

There will be 3 randomized, double-blinded clinical trials to help determine which of commonly prescribed oral opioid combination is most effective in managing acute extremity pain after discharge from the adult emergency department. The first trial compares hydrocodone 5mg / acetaminophen 500mg to codeine 30mg/acetaminophen 300mg. The second trial compares oxycodone 5mg/acetaminophen 325mg to codeine 30mg/acetaminophen 300mg. The third trial compares oxycodone 5mg/acetaminophen 325 mg to hydrocodone 5mg/acetaminophen 325 mg.

Detailed description

Eligible patients are those between the ages of 21 and 64 who present to the Emergency Department (ED) with a complaint of acute extremity pain of less than seven days duration in one or more extremities and for whom the clinician plans to discharge on an oral opioid for pain management. Patients will be excluded if they have ever taken methadone; have a chronic condition requiring frequent pain management such as sickle cell disease, fibromyalgia, or any neuropathy; report a history of an adverse reaction to any of the study medications; if they have taken prescribed opioids in the past 24 hours or if they report having ever taken recreational narcotics; if they have a medical condition that might affect their metabolism of opioid analgesics or acetaminophen; or if they take any medicine that might interact with one of the study medications. Patients will be referred by the attending physician or clinician and consent as well as the initial and follow-up data collections will be obtained by our team of trained bilingual (Spanish and English) salaried research associates who staff the ED 24 hours a day and 7 days a week. In the first study, patients will be randomized to one of two experimental groups: hydrocodone 5mg / acetaminophen 500mg or codeine 30mg / acetaminophen 300mg. Randomization will be performed in blocks of 10 and determined by a sequence generated at http://www.randomization.com. The pharmacist working in an area inaccessible to ED staff will ensure proper blinding of the study by masking the medication and inserting it into unmarked gel capsules and filling any void with small amounts of lactose. A three-day supply (18 doses) of the blinded medications will be dispensed by the ED staff to the patient in the order determined by randomization accompanied by instructions to use one tablet of the medication every 4 hours as needed for pain and to avoid use of any other analgesics. Using a power of 80%, a significance criterion of 0.5, and an estimated delta of 1.3 NRS units, a sample size of 85 patients per group. In order to account for those that do not end up taking the medicine, it is estimated that 120 patients per group will have to be enrolled. Data will be collected on a standardized data collection instrument, entered by a trained data clerk, and reviewed and audited for accuracy and completeness. The investigators will calculate descriptive statistics for all variables: frequencies, means and standard deviations, medians and IQR, and proportions. Chi-square tests will be used to test differences between dichotomous variables, t-tests will be used to test mean differences. Multivariate models will be used if there are background variables that are unevenly distributed between the two groups. Variables associated with group membership with probability of 0.20 or less will be included in OLS multivariate regression or logistic regression models in order to test the role of group membership while accounting for chance baseline disparities. Interaction terms will be tested and dropped from the models if they were not statically significant at the 0.05 level. SPSS version 17 (Chicago, IL.) will be used to conduct all data analyses. The second trial will be identical to the first trial with the exception of one of the study drugs, which will be oxycodone 5mg / acetaminophen 325 mg which will be compared to codeine 30mg / acetaminophen 300mg. The third trial will be identical to the first and second trials with the exception of study drugs. This study will use oxycodone 5 mg/acetaminophen 325mg and hydrocodone 5mg/acetaminophen 325mg.

Interventions

DRUGHydrocodone (first trial)

Patients will take 1 dose of Hydrocodone 5mg / Acetaminophen 500mg every 4 hours as needed for pain

DRUGCodeine (first trial)

Patients will take 1 dose of Codeine 30 mg / Acetaminophen 300 mg every 4 hours as needed for pain

DRUGOxycodone (for second trial)

Patients will take 1 dose of Oxycodone 5 mg / Acetaminophen 325 mg every 4 hours as needed for pain

DRUGCodeine (for second trial)

Patients will take 1 dose of Codeine 30 mg / Acetaminophen 300 mg every 4 hours as needed for pain

DRUGOxycodone (third trial)

Patients will take 1 dose of Oxycodone 5mg / Acetaminophen 325 mg every 4 hours as needed for pain

DRUGHydrocodone (third trial)

Patients will take 1 dose of Hydrocodone 5 mg / Acetaminophen 325 mg every 4 hours as needed for pain.

Sponsors

Montefiore Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
21 Years to 64 Years
Healthy volunteers
No

Inclusion criteria

* patient has complaint of acute extremity pain (less than 7 days duration) * clinician plans to discharge on oral pain medication

Exclusion criteria

* patients on methadone * chronic pain condition such as sickle cell anemia or fibromyalgia * history of adverse reaction to one of the study medications * taken prescribed opioids in the past 24 hrs * have a medical condition that might alter the metabolism of one of the study medications (i.e. hepatitis, renal insufficiency, thyroid disease, Adrenal disease) * Take a medication that might interact with one of the study medications

Design outcomes

Primary

MeasureTime frameDescription
Difference in Pain Intensity Score Before and After Last Dose.2 hrsPain intensity is measured on the numerical rating scale (NRS) from 0 (no pain) to 10 (worst pain imaginable). The difference in pain score is calculated by subtracting the average score 2 hours after pain medication is taken from the average pain score immediately before the pain medication is taken.

Secondary

MeasureTime frameDescription
Overall Satisfaction With the Pain Medicine24 hrsOverall satisfaction with the oral opioid pain medication at 24 hours after discharge using a Likert scale. Patients will be asked to describe their overall experience as being very satisfied, satisfied, unsatisfied or very unsatisfied with the study medication.

Countries

United States

Participant flow

Participants by arm

ArmCount
Hydrocodone (First Trial)
Hydrocodone 5mg / Acetaminophen 500mg. Patients instructed to take 1 dose every 4 hrs as needed for pain. Hydrocodone (first trial): Patients will take 1 dose of Hydrocodone 5mg / Acetaminophen 500mg every 4 hours as needed for pain
88
Codeine (First Trial)
Codeine 30mg / Acetaminophen 300mg. Patients instructed to take 1 dose every 4 hrs as needed for pain. Codeine (first trial): Patients will take 1 dose of Codeine 30 mg / Acetaminophen 300 mg every 4 hours as needed for pain
93
Oxycodone (for Second Trial)
Oxycodone 5mg / Acetaminophen 325mg. Patients instructed to take 1 dose every 4 hrs as needed for pain. Oxycodone (for second trial): Patients will take 1 dose of Oxycodone 5 mg / Acetaminophen 325 mg every 4 hours as needed for pain
111
Codeine (for Second Trial)
Codeine 30mg / Acetaminophen 300mg. Patients instructed to take 1 dose every 4 hrs as needed for pain. Codeine (for second trial): Patients will take 1 dose of Codeine 30 mg / Acetaminophen 300 mg every 4 hours as needed for pain
104
Oxycodone (Third Trial)
Oxycodone 5mg / Acetaminophen 325 mg. Patients instructed to take 1 dose every 4 hours as needed for pain. Oxycodone (third trial): Patients will take 1 dose of Oxycodone 5mg / Acetaminophen 325 mg every 4 hours as needed for pain
107
Hydrocodone (Third Trial)
Hydrocodone 5mg / Acetaminophen 325 mg. Patients instructed to take 1 dose every 4 hours as needed for pain. Hydrocodone (third trial): Patients will take 1 dose of Hydrocodone 5 mg / Acetaminophen 325 mg every 4 hours as needed for pain.
113
Total616

Baseline characteristics

CharacteristicCodeine (First Trial)TotalHydrocodone (First Trial)Hydrocodone (Third Trial)Oxycodone (Third Trial)Codeine (for Second Trial)Oxycodone (for Second Trial)
Age, Continuous37 years
STANDARD_DEVIATION 11
38 years
STANDARD_DEVIATION 12
34 years
STANDARD_DEVIATION 12
38 years
STANDARD_DEVIATION 13
39 years
STANDARD_DEVIATION 12
38 years
STANDARD_DEVIATION 11
39 years
STANDARD_DEVIATION 12
Diagnosis
Extremity Fracture
17 Participants228 Participants20 Participants58 Participants63 Participants37 Participants33 Participants
Diagnosis
Other
22 Participants105 Participants28 Participants13 Participants5 Participants18 Participants19 Participants
Diagnosis
Sprain/strain
54 Participants283 Participants40 Participants42 Participants39 Participants49 Participants59 Participants
NRS pain intensity score on discharge7 units on a scale7 units on a scale7 units on a scale8 units on a scale8 units on a scale7 units on a scale7 units on a scale
NRS pain intensity score on ED arrival9 units on a scale10 units on a scale9 units on a scale10 units on a scale10 units on a scale10 units on a scale10 units on a scale
Race/Ethnicity, Customized
African American
18 Participants167 Participants27 Participants28 Participants32 Participants27 Participants35 Participants
Race/Ethnicity, Customized
Hispanic
69 Participants402 Participants56 Participants73 Participants67 Participants71 Participants66 Participants
Race/Ethnicity, Customized
Other
6 Participants47 Participants5 Participants12 Participants8 Participants6 Participants10 Participants
Region of Enrollment
United States
93 Participants616 Participants88 Participants113 Participants107 Participants104 Participants111 Participants
Sex: Female, Male
Female
48 Participants314 Participants38 Participants48 Participants60 Participants58 Participants62 Participants
Sex: Female, Male
Male
45 Participants302 Participants50 Participants65 Participants47 Participants46 Participants49 Participants
Took analgesic prior to presentation
No
63 Participants418 Participants63 Participants74 Participants76 Participants70 Participants72 Participants
Took analgesic prior to presentation
Unknown
3 Participants12 Participants1 Participants3 Participants2 Participants1 Participants2 Participants
Took analgesic prior to presentation
Yes
27 Participants186 Participants24 Participants36 Participants29 Participants33 Participants37 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
EG004
affected / at risk
EG005
affected / at risk
deaths
Total, all-cause mortality
0 / 880 / 930 / 1110 / 1040 / 1070 / 113
other
Total, other adverse events
54 / 8851 / 9368 / 11161 / 10474 / 10651 / 112
serious
Total, serious adverse events
0 / 880 / 930 / 1110 / 1040 / 1070 / 113

Outcome results

Primary

Difference in Pain Intensity Score Before and After Last Dose.

Pain intensity is measured on the numerical rating scale (NRS) from 0 (no pain) to 10 (worst pain imaginable). The difference in pain score is calculated by subtracting the average score 2 hours after pain medication is taken from the average pain score immediately before the pain medication is taken.

Time frame: 2 hrs

ArmMeasureGroupValue (MEAN)Dispersion
Hydrocodone (First Trial)Difference in Pain Intensity Score Before and After Last Dose.2 hours after most recent dose3.6 units on a scaleStandard Deviation 2.8
Hydrocodone (First Trial)Difference in Pain Intensity Score Before and After Last Dose.before most recent dose7.6 units on a scaleStandard Deviation 1.7
Hydrocodone (First Trial)Difference in Pain Intensity Score Before and After Last Dose.change in NRS before to after most recent dose3.9 units on a scaleStandard Deviation 2.5
Codeine (First Trial)Difference in Pain Intensity Score Before and After Last Dose.2 hours after most recent dose4.1 units on a scaleStandard Deviation 2.9
Codeine (First Trial)Difference in Pain Intensity Score Before and After Last Dose.before most recent dose7.6 units on a scaleStandard Deviation 1.8
Codeine (First Trial)Difference in Pain Intensity Score Before and After Last Dose.change in NRS before to after most recent dose3.5 units on a scaleStandard Deviation 2.6
Oxycodone (for Second Trial)Difference in Pain Intensity Score Before and After Last Dose.2 hours after most recent dose3.4 units on a scaleStandard Deviation 2.5
Oxycodone (for Second Trial)Difference in Pain Intensity Score Before and After Last Dose.before most recent dose7.9 units on a scaleStandard Deviation 1.5
Oxycodone (for Second Trial)Difference in Pain Intensity Score Before and After Last Dose.change in NRS before to after most recent dose4.5 units on a scaleStandard Deviation 2.4
Codeine (for Second Trial)Difference in Pain Intensity Score Before and After Last Dose.2 hours after most recent dose3.6 units on a scaleStandard Deviation 4.2
Codeine (for Second Trial)Difference in Pain Intensity Score Before and After Last Dose.before most recent dose7.9 units on a scaleStandard Deviation 1.7
Codeine (for Second Trial)Difference in Pain Intensity Score Before and After Last Dose.change in NRS before to after most recent dose4.2 units on a scaleStandard Deviation 2.4
Oxycodone (Third Trial)Difference in Pain Intensity Score Before and After Last Dose.2 hours after most recent dose3.3 units on a scaleStandard Deviation 2.7
Oxycodone (Third Trial)Difference in Pain Intensity Score Before and After Last Dose.before most recent dose7.8 units on a scaleStandard Deviation 1.5
Oxycodone (Third Trial)Difference in Pain Intensity Score Before and After Last Dose.change in NRS before to after most recent dose4.4 units on a scaleStandard Deviation 2.5
Hydrocodone (Third Trial)Difference in Pain Intensity Score Before and After Last Dose.before most recent dose7.6 units on a scaleStandard Deviation 1.6
Hydrocodone (Third Trial)Difference in Pain Intensity Score Before and After Last Dose.change in NRS before to after most recent dose4.0 units on a scaleStandard Deviation 2.5
Hydrocodone (Third Trial)Difference in Pain Intensity Score Before and After Last Dose.2 hours after most recent dose3.6 units on a scaleStandard Deviation 2.6
Secondary

Overall Satisfaction With the Pain Medicine

Overall satisfaction with the oral opioid pain medication at 24 hours after discharge using a Likert scale. Patients will be asked to describe their overall experience as being very satisfied, satisfied, unsatisfied or very unsatisfied with the study medication.

Time frame: 24 hrs

Population: Any number analyzed that does not equal the overall number of participants is due to missing data

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Hydrocodone (First Trial)Overall Satisfaction With the Pain MedicineNumber of participants satisfied with analgesic72 Participants
Hydrocodone (First Trial)Overall Satisfaction With the Pain Medicineparticipants would want the same analgesic again59 Participants
Codeine (First Trial)Overall Satisfaction With the Pain MedicineNumber of participants satisfied with analgesic66 Participants
Codeine (First Trial)Overall Satisfaction With the Pain Medicineparticipants would want the same analgesic again66 Participants
Oxycodone (for Second Trial)Overall Satisfaction With the Pain MedicineNumber of participants satisfied with analgesic99 Participants
Oxycodone (for Second Trial)Overall Satisfaction With the Pain Medicineparticipants would want the same analgesic again91 Participants
Codeine (for Second Trial)Overall Satisfaction With the Pain MedicineNumber of participants satisfied with analgesic91 Participants
Codeine (for Second Trial)Overall Satisfaction With the Pain Medicineparticipants would want the same analgesic again85 Participants
Oxycodone (Third Trial)Overall Satisfaction With the Pain MedicineNumber of participants satisfied with analgesic93 Participants
Oxycodone (Third Trial)Overall Satisfaction With the Pain Medicineparticipants would want the same analgesic again86 Participants
Hydrocodone (Third Trial)Overall Satisfaction With the Pain MedicineNumber of participants satisfied with analgesic97 Participants
Hydrocodone (Third Trial)Overall Satisfaction With the Pain Medicineparticipants would want the same analgesic again90 Participants
Post Hoc

50% or Greater Decrease in Numerical Rating Scale (NRS) Pain Score

Time frame: 2 hours

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Hydrocodone (First Trial)50% or Greater Decrease in Numerical Rating Scale (NRS) Pain Score50 Participants
Codeine (First Trial)50% or Greater Decrease in Numerical Rating Scale (NRS) Pain Score45 Participants
Oxycodone (for Second Trial)50% or Greater Decrease in Numerical Rating Scale (NRS) Pain Score73 Participants
Codeine (for Second Trial)50% or Greater Decrease in Numerical Rating Scale (NRS) Pain Score64 Participants
Oxycodone (Third Trial)50% or Greater Decrease in Numerical Rating Scale (NRS) Pain Score68 Participants
Hydrocodone (Third Trial)50% or Greater Decrease in Numerical Rating Scale (NRS) Pain Score66 Participants
Post Hoc

Time to Follow up

Median time to contact patients for data collection, measured from discharge to time contacted

Time frame: up to 48 hours

ArmMeasureValue (MEDIAN)
Hydrocodone (First Trial)Time to Follow up27 hours
Codeine (First Trial)Time to Follow up25 hours
Oxycodone (for Second Trial)Time to Follow up26 hours
Codeine (for Second Trial)Time to Follow up28 hours
Oxycodone (Third Trial)Time to Follow up27 hours
Hydrocodone (Third Trial)Time to Follow up28 hours

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026